Zolimomab aritox
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Mouse |
| Target | CD5 |
| Clinical data | |
| ATC code | none |
| Identifiers | |
| CAS Number |
141483-72-9  |
| ChemSpider | none |
| KEGG |
D06381  |
| (what is this?) (verify) | |
Zolimomab aritox is a mouse monoclonal antibody which has been investigated for the treatment of systemic lupus erythematosus[1] and graft-versus-host disease,[2] but the studies failed to show positive effects of the drug.
It is an anti-CD5 antibody which is linked to the A chain of the ricin protein (which is reflected by the aritox in the drug's name).[3]
See also
References
- ↑ Stafford, FJ; Fleisher, TA; Lee, G; Brown, M; Strand, V; Austin Ha, 3rd; Balow, JE; Klippel, JH (1994). "A pilot study of anti-CD5 ricin a chain immunoconjugate in systemic lupus erythematosus". The Journal of rheumatology. 21 (11): 2068–70. PMID 7532717.
- ↑ Przepiorka, D; Lemaistre, CF; Huh, YO; Luna, M; Saria, EA; Brown, CT; Champlin, RE (1994). "Evaluation of anti-CD5 ricin a chain immunoconjugate for prevention of acute graft-vs.-host disease after HLA-identical marrow transplantation". Therapeutic immunology. 1 (2): 77–82. PMID 7584486.
- ↑ WHO Drug Information
This article is issued from Wikipedia - version of the 10/6/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.